AD
MCID: ALZ034
MIFTS: 92

Alzheimer Disease (AD) malady

Categories: Genetic diseases, Rare diseases, Mental diseases, Neuronal diseases

Aliases & Classifications for Alzheimer Disease

Aliases & Descriptions for Alzheimer Disease:

Name: Alzheimer Disease 54 12 23 50 24 25 66 42 38
Alzheimer's Disease 38 12 71 25 51 41 3 14 69
Alzheimer Disease 8 54 12 13 69
Alzheimer's Disease 6 12 29 14
Alzheimer Disease 6 54 12 13
Ad 12 25 66
Alzheimer Disease 1, Familial 54 13
Presenile and Senile Dementia 25 66
Familial Alzheimer Disease 25 69
Alzheimer's Disease 10 12 14
Alzheimer's Disease 5 12 14
Alzheimer's Disease 8 12 14
Alzheimer Disease-10 54 13
Alzheimer Disease 10 12 69
Alzheimer Disease 5 12 69
Alzheimer Syndrome 25 29
Ad5 12 24
Early-Onset Alzheimer Disease with Cerebral Amyloid Angiopathy 66
Alzheimer Disease, Pathogenesis, Association with 54
Alzheimer Disease, Susceptibility to 24
Primary Senile Degenerative Dementia 25
Autosomal Dominant Alzheimer Disease 66
Alzheimer Disease, Familial, Type 5 13
Dementia Due to Alzheimer's Disease 69
Alzheimer's Disease Pathway Kegg 69
Alzheimer Disease 9, Late Onset 54
Alzheimer Disease 6, Late Onset 12
Alzheimer Disease 6, Late-Onset 69
Alzheimer Disease, Late-Onset 54
Alzheimer Disease, Familial 5 12
Alzheimer Disease, Familial 8 12
Alzheimer Disease Familial 10 12
Alzheimer Disease, Familial 12
Alzheimer Disease Type 1 69
Alzheimer Disease Type 5 24
Alzheimer-Type Dementia 25
Alzheimer Disease-5 54
Alzheimers Dementia 12
Alzheimer Disease 1 66
Alzheimer Sclerosis 25
Alzheimer Dementia 25
Alzheimers Disease 52
Ad10 12
Ad 5 24
Sdat 25
Ad6 12
Ad8 12
Ad1 66
Dat 25

Characteristics:

HPO:

32
alzheimer disease:
Inheritance autosomal dominant inheritance heterogeneous
Onset and clinical course late onset


Classifications:



Summaries for Alzheimer Disease

OMIM : 54 Alzheimer disease is the most common form of progressive dementia in the elderly. It is a neurodegenerative disorder... (104300) more...

MalaCards based summary : Alzheimer Disease, also known as alzheimer's disease, is related to pick disease and early-onset, autosomal dominant alzheimer disease, and has symptoms including personality changes, neurological speech impairment and cerebral cortical atrophy. An important gene associated with Alzheimer Disease is APP (Amyloid Beta Precursor Protein), and among its related pathways/superpathways are Alzheimer's disease and Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins.. The drugs Galantamine and Donepezil have been mentioned in the context of this disorder. Affiliated tissues include Brain and Blood, and related phenotypes are behavior/neurological and homeostasis/metabolism

Disease Ontology : 12 A tauopathy that is characterized by memory lapses, confusion, emotional instability and progressive loss of mental ability and results in progressive memory loss, impaired thinking, disorientation, and changes in personality and mood starting and leads in advanced cases to a profound decline in cognitive and physical functioning and is marked histologically by the degeneration of brain neurons especially in the cerebral cortex and by the presence of neurofibrillary tangles and plaques containing beta-amyloid.

Genetics Home Reference : 25 Alzheimer disease is a degenerative disease of the brain that causes dementia, which is a gradual loss of memory, judgment, and ability to function. This disorder usually appears in people older than age 65, but less common forms of the disease appear earlier in adulthood.

NIH Rare Diseases : 50 alzheimer disease (ad) is a degenerative disease of the brain that causes gradual loss of memory, judgment, and the ability to function socially. alzheimer disease currently affects about 5 million people. about 75 percent of alzheimer disease cases are classified as sporadic, which means they occur in people with no history of the disorder in their family. although the cause of these cases is unknown, genetic changes are likely to play a role. virtually all sporadic cases of alzheimer disease begin after age 65, and the risk of developing this condition increases as a person gets older. ad can be subdivided into two groups based on the age of onset: (1) early-onset (1%-6% of the cases) which start in people younger than 60- 65 years of age (2) late-onset, which starts in people older than 65 years old. in about 25% of cases, ad is familial (2 or more people in a family have ad). for more information, please visit gard's familial alzheimer disease web page. last updated: 11/2/2015

MedlinePlus : 41 alzheimer's disease (ad) is the most common form of dementia among older people. dementia is a brain disorder that seriously affects a person's ability to carry out daily activities. ad begins slowly. it first involves the parts of the brain that control thought, memory and language. people with ad may have trouble remembering things that happened recently or names of people they know. a related problem, mild cognitive impairment (mci), causes more memory problems than normal for people of the same age. many, but not all, people with mci will develop ad. in ad, over time, symptoms get worse. people may not recognize family members. they may have trouble speaking, reading or writing. they may forget how to brush their teeth or comb their hair. later on, they may become anxious or aggressive, or wander away from home. eventually, they need total care. this can cause great stress for family members who must care for them. ad usually begins after age 60. the risk goes up as you get older. your risk is also higher if a family member has had the disease. no treatment can stop the disease. however, some drugs may help keep symptoms from getting worse for a limited time. nih: national institute on aging

CDC : 3 The most common form of dementia. A progressive disease beginning with mild memory loss possibly leading to loss of the ability to carry on a conversation and respond to the environment. Involves parts of the brain that control thought, memory, and language. Can seriously affect a person’s ability to carry out daily activities. Although scientists are learning more every day, right now, they still do not know what causes Alzheimer’s disease.

NINDS : 51 Alzheimer's disease (AD) is an age-related, non-reversible brain disorder that develops over a period of years. Initially, people experience memory loss and confusion, which may be mistaken for the kinds of memory changes that are sometimes associated with normal aging. However, the symptoms of AD gradually lead to behavior and personality changes, a decline in cognitive abilities such as decision-making and language skills, and problems recognizing family and friends. AD ultimately leads to a severe loss of mental function. These losses are related to the worsening breakdown of the connections between certain neurons in the brain and their eventual death. AD is one of a group of disorders called  that are characterized by cognitive and behavioral problems. It is the most common cause of dementia among people age 65 and older.

UniProtKB/Swiss-Prot : 66 Alzheimer disease: Alzheimer disease is a neurodegenerative disorder characterized by progressive dementia, loss of cognitive abilities, and deposition of fibrillar amyloid proteins as intraneuronal neurofibrillary tangles, extracellular amyloid plaques and vascular amyloid deposits. The major constituent of these plaques is the neurotoxic amyloid-beta-APP 40-42 peptide (s), derived proteolytically from the transmembrane precursor protein APP by sequential secretase processing. The cytotoxic C- terminal fragments (CTFs) and the caspase-cleaved products such as C31 derived from APP, are also implicated in neuronal death. Alzheimer disease 1: A familial early-onset form of Alzheimer disease. It can be associated with cerebral amyloid angiopathy. Alzheimer disease is a neurodegenerative disorder characterized by progressive dementia, loss of cognitive abilities, and deposition of fibrillar amyloid proteins as intraneuronal neurofibrillary tangles, extracellular amyloid plaques and vascular amyloid deposits. The major constituent of these plaques is the neurotoxic amyloid-beta-APP 40-42 peptide (s), derived proteolytically from the transmembrane precursor protein APP by sequential secretase processing. The cytotoxic C-terminal fragments (CTFs) and the caspase-cleaved products such as C31 derived from APP, are also implicated in neuronal death.

Wikipedia : 71 Alzheimer\'s disease (AD), also referred to simply as Alzheimer\'s, is a chronic neurodegenerative... more...

GeneReviews: NBK1161

Related Diseases for Alzheimer Disease

Diseases in the Alzheimer Disease family:

Alzheimer Disease-4 Alzheimer Disease 17
Alzheimer Disease 12 Alzheimer Disease, Type 3
Alzheimer Disease 18 Alzheimer Disease-2
Alzheimer Disease 19, Late Onset Alzheimer Disease 16
Alzheimer's Disease 7 Alzheimer's Disease 11
Alzheimer's Disease 13 Alzheimer's Disease 14
Alzheimer's Disease 15 Early-Onset Familial Alzheimer Disease
Alzheimer Disease Type 1 Early-Onset, Autosomal Dominant Alzheimer Disease
Alzheimer Disease Risk Factor

Diseases related to Alzheimer Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 148)
id Related Disease Score Top Affiliating Genes
1 pick disease 30.4 APP PSEN1 PSEN2
2 early-onset, autosomal dominant alzheimer disease 12.4
3 alzheimer disease, type 3 12.3
4 alzheimer disease 19, late onset 12.1
5 alzheimer disease 18 12.1
6 alzheimer disease mitochondrial 12.0
7 immunodeficiency 27b, mycobacteriosis, ad 12.0
8 alzheimer disease 12 12.0
9 alzheimer disease-2 12.0
10 early-onset familial alzheimer disease 12.0
11 alzheimer disease type 1 11.9
12 alzheimer disease 17 11.9
13 alzheimer disease 16 11.8
14 renal tubular acidosis, distal, ad 11.8
15 keratosis palmoplantaris striata i, ad 11.8
16 alzheimer disease risk factor 11.8
17 familial mediterranean fever, ad 11.7
18 emery-dreifuss muscular dystrophy 2, ad 11.7
19 cutis laxa, ad 11.7
20 slowed nerve conduction velocity, ad 11.7
21 spinal muscular atrophy, lower extremity-predominant, 2, ad 11.7
22 emery-dreifuss muscular dystrophy 7, ad 11.7
23 epidermolysis bullosa dystrophica, ad 11.7
24 alzheimer disease-4 11.7
25 dopa-responsive dystonia; segawa syndrome ad 11.7
26 spinal muscular atrophy, lower extremity-predominant 1, ad 11.7
27 hyper-ige recurrent infection syndrome 11.6
28 dementia, lewy body 11.4
29 alzheimer's disease 7 11.4
30 alzheimer's disease 11 11.3
31 alzheimer's disease 15 11.3
32 alzheimer's disease 13 11.2
33 alzheimer's disease 14 11.2
34 posterior cortical atrophy 11.1
35 down syndrome 11.1
36 schizophrenia 11.0
37 supranuclear palsy, progressive 10.8
38 frontotemporal lobar degeneration with ubiquitin-positive inclusions 10.8
39 parkinson disease 1 10.7
40 parkinson disease, late-onset 10.7
41 acne inversa, familial, 1 10.7
42 cerebral amyloid angiopathy, dutch, italian, iowa, flemish, arctic variants 10.7
43 dementia, frontotemporal 10.7
44 dementia, familial, nonspecific 10.7
45 meckel syndrome 10 10.6 APP GSK3B MAPT NOS3 PLAU PSEN1
46 cardiomyopathy, dilated, 1u 10.6 APP BACE1 MAPT PSEN1 PSEN2 SNCA
47 substance-induced psychosis 10.6 APP BACE1 MAPT PSEN1 PSEN2 SNCA
48 eumycotic mycetoma 10.6 APP MAPT PSEN1 PSEN2 SNCA
49 epithelioid type angiomyolipoma 10.6 APP BACE1 MAPT PSEN1 SNCA
50 ectodermal dysplasia mental retardation syndactyly 10.6 APP PSEN1 PSEN2 SORL1

Comorbidity relations with Alzheimer Disease via Phenotypic Disease Network (PDN): (show top 50) (show all 54)


Active Peptic Ulcer Disease Acute Conjunctivitis
Acute Cystitis Acute Kidney Failure
Amnestic Disorder Bronchitis
Bronchopneumonia Cerebral Atherosclerosis
Cerebral Degeneration Cerebrovascular Disease
Communicating Hydrocephalus Conduct Disorder
Conjunctivitis Cystitis
Decubitus Ulcer Deficiency Anemia
Delusional Disorder Dental Caries
Dermatomycosis Encephalopathy
Fecal Incontinence Folic Acid Deficiency Anemia
Generalized Atherosclerosis Grn-Related Frontotemporal Dementia
Heart Disease Hypoglycemia
Hypothyroidism Intermittent Explosive Disorder
Intestinal Volvulus Iron Deficiency Anemia
Kidney Disease Kohlschutter-Tonz Syndrome
Latent Syphilis Marasmus
Neurogenic Bladder Nutritional Deficiency Disease
Obstructive Hydrocephalus Ocular Motor Apraxia
Oral Candidiasis Osteoporosis
Paralytic Ileus Paranoid Schizophrenia
Parkinson Disease, Late-Onset Pernicious Anemia
Personality Disorder Protein-Energy Malnutrition
Pyelonephritis Scabies
Schizophrenia Schizophreniform Disorder

Graphical network of the top 20 diseases related to Alzheimer Disease:



Diseases related to Alzheimer Disease

Symptoms & Phenotypes for Alzheimer Disease

Symptoms by clinical synopsis from OMIM:

104300

Clinical features from OMIM:

104300

Human phenotypes related to Alzheimer Disease:

32 (show all 10)
id Description HPO Frequency HPO Source Accession
1 personality changes 32 HP:0000751
2 neurological speech impairment 32 HP:0002167
3 cerebral cortical atrophy 32 HP:0002120
4 memory impairment 32 HP:0002354
5 dementia 32 HP:0000726
6 parkinsonism 32 HP:0001300
7 neurofibrillary tangles 32 HP:0002185
8 senile plaques 32 HP:0100256
9 long-tract signs 32 HP:0002423
10 alzheimer disease 32 HP:0002511

UMLS symptoms related to Alzheimer Disease:


angina pectoris, back pain, headache, myoclonus, pain, sciatica, seizures, syncope, tremor, chronic pain, vertigo/dizziness, equilibration disorder, sleeplessness, personality changes

MGI Mouse Phenotypes related to Alzheimer Disease:

44 (show all 12)
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.32 ACE APP BACE1 BLMH GSK3B HFE
2 homeostasis/metabolism MP:0005376 10.28 PSEN1 PSEN2 SNCA SORL1 ACE APBB2
3 growth/size/body region MP:0005378 10.27 NOS3 PLAU PSEN1 PSEN2 SNCA ACE
4 cardiovascular system MP:0005385 10.24 GSK3B MAPT MPO NOS3 PLAU PSEN1
5 mortality/aging MP:0010768 10.17 PSEN2 SNCA ACE APBB2 APP BACE1
6 immune system MP:0005387 10.15 ACE APP BLMH GSK3B HFE MAPT
7 hematopoietic system MP:0005397 10.13 MAPT MPO NOS3 PLAU PSEN1 PSEN2
8 digestive/alimentary MP:0005381 10.02 GSK3B HFE NOS3 PLAU PSEN1 PSEN2
9 nervous system MP:0003631 9.93 APBB2 APP BACE1 GSK3B HFE MAPT
10 muscle MP:0005369 9.86 APP BACE1 MAPT MPO NOS3 PLAU
11 normal MP:0002873 9.65 APBB2 APP BACE1 GSK3B HFE MAPT
12 renal/urinary system MP:0005367 9.17 ACE GSK3B MAPT NOS3 PSEN1 PSEN2

Drugs & Therapeutics for Alzheimer Disease

Drugs for Alzheimer Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 644)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Galantamine Approved Phase 4,Phase 3,Phase 2,Phase 1 357-70-0 9651 908828, 9651
2
Donepezil Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 120014-06-4 3152
3
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51-61-6, 62-31-7 681
4
Memantine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 19982-08-2 4054
5
Benzocaine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 1994-09-7, 94-09-7 2337
6
Risperidone Approved, Investigational Phase 4,Phase 3,Phase 2 106266-06-2 5073
7
Citalopram Approved Phase 4,Phase 3,Phase 2 59729-33-8 2771
8
Rivastigmine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 123441-03-2 77991
9
Methylphenidate Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 113-45-1 4158
10
Levodopa Approved Phase 4 59-92-7 6047
11
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 1 50-78-2 2244
12
Rivaroxaban Approved Phase 4 366789-02-8
13
Ticagrelor Approved Phase 4,Phase 3 274693-27-5 9871419
14
Warfarin Approved Phase 4,Phase 3,Phase 1 81-81-2 6691 54678486
15
Amlodipine Approved Phase 4,Phase 2,Phase 3 88150-42-9 2162
16
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 50-28-2 5757 53477783
17
Medroxyprogesterone acetate Approved, Investigational Phase 4,Phase 2,Phase 3 71-58-9
18
Progesterone Approved, Vet_approved Phase 4,Phase 2,Phase 3 57-83-0 5994
19
Nicotine Approved Phase 4,Phase 2,Phase 3,Phase 1 54-11-5 942 89594
20
Ibuprofen Approved Phase 4,Phase 3,Phase 1,Early Phase 1 15687-27-1 3672
21
Guaifenesin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 93-14-1 3516
22
Acetylcholine Approved Phase 4,Phase 3,Phase 2,Phase 1 51-84-3 187
23
Hydroxocobalamin Approved Phase 4,Phase 3,Phase 2 13422-51-0 11953898 5460373 44475014
24
Isoflurane Approved, Vet_approved Phase 4,Phase 1 26675-46-7 3763
25
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 1 2078-54-8 4943
26
Dextromethorphan Approved Phase 4,Phase 3,Phase 2,Phase 1 125-71-3 5360696 5362449
27
Valproic Acid Approved, Investigational Phase 4,Phase 3,Phase 1,Early Phase 1 99-66-1 3121
28
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
29
Dextroamphetamine Approved, Illicit Phase 4 51-64-9 5826
30
Haloperidol Approved Phase 4,Phase 3 52-86-8 3559
31
Nicergoline Approved Phase 4 27848-84-6 34040
32 Piracetam Approved Phase 4,Phase 2 7491-74-9
33
Cilostazol Approved Phase 4,Phase 2 73963-72-1 2754
34
Ramipril Approved Phase 4 87333-19-5 5362129
35
Sertraline Approved Phase 4,Phase 2,Phase 3 79617-96-2 68617
36
Pravastatin Approved Phase 4 81093-37-0 54687
37
Simvastatin Approved Phase 4,Phase 3,Phase 2,Phase 1 79902-63-9 54454
38
Atropine Approved, Vet_approved Phase 4 5908-99-6, 51-55-8 174174
39
Olanzapine Approved, Investigational Phase 4 132539-06-1 4585
40
Norepinephrine Approved Phase 4,Phase 1 51-41-2 439260
41
Aripiprazole Approved, Investigational Phase 4,Phase 3,Phase 1 129722-12-9 60795
42
Acetaminophen Approved Phase 4,Phase 3,Phase 2 103-90-2 1983
43
Hydrocodone Approved, Illicit Phase 4 125-29-1 5284569
44
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
45
Nimodipine Approved Phase 4 66085-59-4 4497
46
Lamotrigine Approved, Investigational Phase 4 84057-84-1 3878
47
Rasagiline Approved Phase 4,Phase 2 136236-51-6 3052776
48
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4 52485-79-7 40400 644073
49
Atenolol Approved Phase 4 29122-68-7 2249
50
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639

Interventional clinical trials:

(show top 50) (show all 2181)
id Name Status NCT ID Phase
1 Diffusion Tensor Weighted MRI in Alzheimer's Disease Modifying Treatment Effects of Galantamine (Reminyl®) Unknown status NCT00523666 Phase 4
2 Donepezil and Memantine in Moderate to Severe Alzheimer's Disease Unknown status NCT00866060 Phase 4
3 Effect of Memantine Oral Pump on Language in Patients With Probable Alzheimer's Disease Unknown status NCT01849042 Phase 4
4 Effect of Cognitive Intervention in Alzheimer's Disease (AD) on Functional Cortical Networks in fMRI Unknown status NCT01329601 Phase 4
5 The Relationship Between Risperdal Treatment and Quality of Life in Patients With Alzheimer's Disease and Behavioural and Psychological Symptoms of Dementia (BPSD) Unknown status NCT00626613 Phase 4
6 Study of Escitalopram Versus Placebo in the Treatment of Depressive Syndrome in Alzheimer’s Disease, Vascular Dementia, and Mixed Vascular and Alzheimer’s Dementia Unknown status NCT00229333 Phase 4
7 Open Label Trial of Rivastigmine Patch in Subjects With Mild to Moderate Stage AD Having Coexisting svCVD Unknown status NCT02444637 Phase 4
8 CALM-AD Unknown status NCT00142324 Phase 4
9 Improving Function, Quality of Life, Glycemia in Diabetics With Dementia Unknown status NCT00792662 Phase 4
10 Dopaminergic Enhancement of Learning and Memory in Healthy Adults and Patients With Dementia/Mild Cognitive Impairment Unknown status NCT00306124 Phase 4
11 Validation of DaTscan for Detection of Parkinson Disease Related Disorders Unknown status NCT02138682 Phase 4
12 Rivaroxaban in Patients With Atrial Fibrillation and Coronary Artery Disease Undergoing Percutaneous Coronary Intervention Unknown status NCT02334254 Phase 4
13 Memantine for Agitation in Dementia Unknown status NCT00371059 Phase 4
14 Huperzine-A to Help With Mental Problems and the Inability to Care for Onself in Patients With Schizophrenia Unknown status NCT01012830 Phase 4
15 Gastrodin Prevents Cognitive Decline Related to Cardiopulmonary Bypass Unknown status NCT00297245 Phase 4
16 Memantine for Post-Operative Pain Control Unknown status NCT01041313 Phase 4
17 Pharmacodynamic Effects of Atorvastatin vs. Rosuvastatin on Platelet Reactivity Unknown status NCT01567774 Phase 4
18 Multi-centre Clinical Trial on Hormone Replacement Treatment in China Unknown status NCT01698164 Phase 4
19 The Clinical Response of Choline Acetyltransferase and Apolipoprotein Epsilon Gene Polymorphisms to Donepezil in Alzheimer's Disease Completed NCT00381381 Phase 4
20 Compliance and Tolerability of Rivastigmine Transdermal Patch 10 cm² in Patients With Probable Alzheimer's Disease. Completed NCT00731224 Phase 4
21 Efficacy, Safety and Tolerability of Rivastigmine Patch in Patients With Mild to Moderate Alzheimer's Disease Switched From Cholinesterase Inhibitors Completed NCT01529619 Phase 4
22 Safety and Efficacy of Donepezil HCl 23 mg in Patients With Moderate to Severe Alzheimer's Disease Completed NCT02097056 Phase 4
23 Memantine and Comprehensive, Individualized Management of Alzheimer's Disease and Caregiver Training Completed NCT00120874 Phase 4
24 A Study of the Effects on Sleep, Attention, and Gastrointestinal Tolerance of Galantamine and Donepezil in Patients With Alzheimer's Disease Completed NCT00035204 Phase 4
25 Double Blind Study of Trp01 in Patients With Alzheimer's Disease Completed NCT00202124 Phase 4
26 16w Interventional Study on Titration and Dose/Efficacy Assessment of Exelon in Chinese Alzheimer's Disease Patients Completed NCT01948791 Phase 4
27 Trial of Carvedilol in Alzheimer's Disease Completed NCT01354444 Phase 4
28 The Efficacy of Galantamine Treatment on Attention in Patients With Alzheimer's Disease Completed NCT01054976 Phase 4
29 Clinical Effectiveness of 10 cm^2 Rivastigmine Patch in Patients With Alzheimer's Disease Completed NCT00561392 Phase 4
30 Delaying the Progression of Driving Impairment in Individuals With Mild Alzheimer's Disease Completed NCT00476008 Phase 4
31 Neural Correlates In Mild Alzheimer's Disease Completed NCT00477659 Phase 4
32 Study of the Effects of Current Drug Treatments on Levels of Certain Brain Chemicals in Alzheimer's Disease Completed NCT00104442 Phase 4
33 Escitalopram for the Treatment of Depression in Alzheimer's Disease Completed NCT01841125 Phase 4
34 A Study to Evaluate Sleep Quality in Patients With Mild to Moderate Alzheimer's Disease Completed NCT01478204 Phase 4
35 Effect of Memantine on Functional Communication in Patients With Alzheimer's Disease Completed NCT00469456 Phase 4
36 The Effectiveness And Safety Of Donepezil Hydrochloride (E2020) In Subjects With Mild To Severe Alzheimer's Disease Residing In An Assisted Living Facility Completed NCT00571064 Phase 4
37 A 12 Week, Multicenter, Open Label Evaluation of Caregiver Preference, Safety and Tolerability of Exelon® Patch (Rivastigmine Transdermal) in Patients With Alzheimer's Disease Completed NCT01047579 Phase 4
38 A 24 Week, Multicenter, Open, Evaluation of the Clinical Effectiveness of the Once-daily 10 cm^2 Rivastigmine Patch Formulation in Patients With Probable Alzheimer's Disease (EXTRA) Completed NCT00622713 Phase 4
39 A Study of the Safety and Effectiveness of Galantamine Hydrobromide in Patients With Alzheimer's Disease Completed NCT00297362 Phase 4
40 Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type (ACTION) (Study Protocol CENA713DUS44, NCT00948766) and a 24 Week Open-label Extension to Study CENA713DUS44 Completed NCT00948766 Phase 4
41 EARTH 413: A Study of Aricept in Hispanic Patients With Mild to Moderate Alzheimer's Disease (AD) Completed NCT00230568 Phase 4
42 Neptune Krill Oil (NKO™) in Early Stage Alzheimer's Disease (MNEMOSYNE) Completed NCT00867828 Phase 4
43 Memantine for Agitation and Aggression in Severe Alzheimer's Disease Completed NCT00401167 Phase 4
44 Magnetic Resonance Spectroscopy Study of Memantine in Alzheimer's Disease Completed NCT00551161 Phase 4
45 A Positron Emission Tomography (PET) Study Evaluating Brain Metabolism of a Medical Food in Alzheimer's Disease Completed NCT01122329 Phase 4
46 Electrophysiologic Measures of Treatment Response in Alzheimer Disease Completed NCT00018278 Phase 4
47 Study of Memantine in Assessment of Selected Measures of Volumetric Magnetic Resonance Imaging (MRI) and Cognition in Moderate AD (Alzheimer's Disease) Completed NCT00334906 Phase 4
48 Effects of Memantine on Magnetic Resonance (MR) Spectroscopy in Subjects at Risk for Alzheimer's Disease Completed NCT00933608 Phase 4
49 Apathy Associated With Alzheimer's Disease Completed NCT00254033 Phase 4
50 A Clinical Study Evaluating the Effects of Memantine on Brain Atrophy in Patients With Alzheimer's Disease Completed NCT00862940 Phase 4

Search NIH Clinical Center for Alzheimer Disease

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Alzheimer Disease cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Alzheimer Disease:
NEUROSTEM
Embryonic/Adult Cultured Cells Related to Alzheimer Disease:
Umbilical cord blood-derived mesenchymal stem/progenitor cells PMIDs: 23293711 22015609

Cochrane evidence based reviews: alzheimer disease

Genetic Tests for Alzheimer Disease

Genetic tests related to Alzheimer Disease:

id Genetic test Affiliating Genes
1 Alzheimer's Disease 29
2 Alzheimer Disease, Type 6 29
3 Alzheimer Disease 29 24
4 Alzheimer Disease, Susceptibility to 24 HFE
5 Alzheimer Disease Type 5 24 AD5

Anatomical Context for Alzheimer Disease

MalaCards organs/tissues related to Alzheimer Disease:

39
Brain, Cortex, Endothelial, Testes, Prostate, Skin, Pons
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Alzheimer Disease:
id Tissue Anatomical CompartmentCell Relevance
1 Brain Forebrain White Matter Fibrous Astrocyte Cells Potential therapeutic candidate, affected by disease
2 Blood Cord Blood Mesenchymal Stem Cells Potential therapeutic candidate
3 Brain Forebrain White Matter Myelinating Oligodendrocyte Cells Affected by disease
4 Brain Neocortex Protoplasmic Astrocyte Cells Potential therapeutic candidate, affected by disease
5 Brain Hippocampus Affected by disease

Publications for Alzheimer Disease

Articles related to Alzheimer Disease:

(show top 50) (show all 1423)
id Title Authors Year
1
Quantitative EEG After Brain Stimulation and Cognitive Training in Alzheimer Disease. ( 28045857 )
2017
2
Combination Therapy with Octyl Gallate and Ferulic Acid Improves Cognition and Neurodegeneration in a Transgenic Mouse Model of Alzheimer Disease. ( 28512130 )
2017
3
Performance of a Condensed Protocol That Reduces Effort and Cost of NIA-AA Guidelines for Neuropathologic Assessment of Alzheimer Disease. ( 28062571 )
2017
4
Multifunctional liposomes delay phenotype progression and prevent memory impairment in a presymptomatic stage mouse model of Alzheimer disease. ( 28501671 )
2017
5
Alzheimer disease: Soluble TREM2 in CSF sheds light on microglial activation in AD. ( 28084325 )
2017
6
Discrimination Between Patients With Alzheimer Disease and Healthy Subjects Using Layer Analysis of Cerebral Blood Flow and Xenon Solubility Coefficient in Xenon-Enhanced Computed Tomography. ( 28505626 )
2017
7
Investigation of gene expression and serum levels of PIN1 and eNOS with high blood pressure in patients with Alzheimer disease. ( 28506742 )
2017
8
Dependence Stage and Pharmacoeconomic Outcomes in Patients With Alzheimer Disease. ( 28486240 )
2017
9
Type 3 Diabetes Mellitus: A Novel Implication of Alzheimer Disease. ( 28049395 )
2017
10
New (benz)imidazolopyridino tacrines as nonhepatotoxic, cholinesterase inhibitors for Alzheimer disease. ( 28485637 )
2017
11
The Relationship Between Copper, Iron, and Selenium Levels and Alzheimer Disease. ( 28500578 )
2017
12
Clinical marker for Alzheimer disease pathology in logopenic primary progressive aphasia. ( 28515265 )
2017
13
Sundown Syndrome, Sleep Quality, and Walking Among Community-Dwelling People With Alzheimer Disease. ( 28057424 )
2017
14
Association of dietary cholesterol and egg intakes with the risk of incident dementia or Alzheimer disease: the Kuopio Ischaemic Heart Disease Risk Factor Study. ( 28052883 )
2017
15
Cerebral blood flow regulation and neurovascular dysfunction in Alzheimer disease. ( 28515434 )
2017
16
Association of traumatic brain injury and Alzheimer disease onset: A systematic review. ( 28506441 )
2017
17
Cell Therapy Products in Alzheimer Disease. ( 28523253 )
2017
18
Insulin Resistance in Alzheimer Disease: p53 and MicroRNAs as Important Players. ( 28049397 )
2017
19
Synaptic Plasticity, Dementia and Alzheimer Disease. ( 28088900 )
2017
20
Predictive Utility of Marketed Volumetric Software Tools in Subjects at Risk for Alzheimer Disease: Do Regions Outside the Hippocampus Matter? ( 28057634 )
2017
21
Heterozygous Deletion of Chorein Exons 70-73 and GNA14 Exons 3-7 in a Brazilian Patient Presenting With Probable Tau-Negative Early-Onset Alzheimer Disease. ( 28079535 )
2017
22
Resistance to Alzheimer Disease Neuropathologic Changes and Apparent Cognitive Resilience in the Nun and Honolulu-Asia Aging Studies. ( 28499012 )
2017
23
Alzheimer disease makes new blood contacts. ( 28473412 )
2017
24
Neuropsychological measures that detect early impairment and decline in preclinical Alzheimer disease. ( 28482211 )
2017
25
Genetic risk for schizophrenia and psychosis in Alzheimer disease. ( 28461698 )
2017
26
Astrocyte dysfunction in Alzheimer disease. ( 28467650 )
2017
27
Gaining Insights into Specific Drug Formulation Additives for Solubilizing a Potential Anti-Alzheimer Disease Drug B4A1. ( 28488401 )
2017
28
The Fall of Sleep K-Complex in Alzheimer Disease. ( 28045040 )
2017
29
Deletion of exons 9 and 10 of the Presenilin 1 gene in a patient with Early-onset Alzheimer Disease generates longer amyloid seeds. ( 28461250 )
2017
30
Aberrant proteolytic processing and therapeutic strategies in Alzheimer disease. ( 28082052 )
2017
31
The transcription factor XBP1 in memory and cognition: Implications in Alzheimer disease. ( 28079229 )
2017
32
Alzheimer disease in 2016: Putting AD treatments and biomarkers to the test. ( 28084326 )
2017
33
Association Between Exercise Capacity and Late Onset of Dementia, Alzheimer Disease, and Cognitive Impairment. ( 28082018 )
2017
34
DNA Methylation Profiles of Selected Pro-Inflammatory Cytokines in Alzheimer Disease. ( 28053004 )
2017
35
Dysregulated metabolism of the amyloid-I^ protein and therapeutic approaches in Alzheimer disease. ( 28488760 )
2017
36
Long-term use of opioids for nonmalignant pain among community-dwelling persons with and without Alzheimer disease in Finland: a nationwide register-based study. ( 28092324 )
2017
37
African American exome sequencing identifies potential risk variants at Alzheimer disease loci. ( 28480329 )
2017
38
Diagnostic Efficacy of Structural MRI in Patients With Mild-to-Moderate Alzheimer Disease: Automated Volumetric Assessment Versus Visual Assessment. ( 28075620 )
2017
39
The Rare-Variant Generalized Disequilibrium Test for Association Analysis of Nuclear and Extended Pedigrees with Application to Alzheimer Disease WGS Data. ( 28065470 )
2017
40
Hippocampal Sclerosis but Not Normal Aging or Alzheimer Disease Is Associated With TDP-43 Pathology in the Basal Forebrain of Aged Persons. ( 26971127 )
2016
41
PET biomarkers: Use of imaging techniques in Alzheimer disease and neurodegeneration clinical diagnosis. ( 27157520 )
2016
42
Autophagic and lysosomal defects in human tauopathies: analysis of post-mortem brain from patients with familial Alzheimer disease, corticobasal degeneration and progressive supranuclear palsy. ( 26936765 )
2016
43
Cerebrospinal Fluid Amyloid Beta and Tau Concentrations Are Not Modulated by 16 Weeks of Moderate- to High-Intensity Physical Exercise in Patients with Alzheimer Disease. ( 27643858 )
2016
44
Treatment of Alzheimer disease: when practice and evidence-based medicine must be capable of dialogue. ( 27651006 )
2016
45
Multi-infarct dementia and Alzheimer disease, contribution of cerebral circulation ultrasonography to pathogenesis and differential diagnosis. Value of microembolisation. ( 27179577 )
2016
46
Thal Amyloid Stages Do Not Significantly Impact the Correlation Between Neuropathological Change and Cognition in the Alzheimer Disease Continuum. ( 27105663 )
2016
47
Cross-interactions between the Alzheimer Disease Amyloid-I^ Peptide and Other Amyloid Proteins: A Further Aspect of the Amyloid Cascade Hypothesis. ( 27325705 )
2016
48
Expression of familial Alzheimer disease presenilin 1 gene attenuates vesicle traffic and reduces peptide secretion in cultured astrocytes devoid of pathologic tissue environment. ( 26462451 )
2016
49
Is cerebral glucose metabolism related to blood-brain barrier dysfunction and intrathecal IgG synthesis in Alzheimer disease?: A 18F-FDG PET/CT study. ( 27631200 )
2016
50
Potential of the Antibody Against cis-Phosphorylated Tau in the Early Diagnosis, Treatment, and Prevention of Alzheimer Disease and Brain Injury. ( 27654282 )
2016